Cabio Biotech Wuhan Co Ltd (688089) — Cash Flow-to-Debt Ratio
Cabio Biotech Wuhan Co Ltd (688089) has a Cash Flow-to-Debt Ratio of 0.31x as of September 2025, meaning its operating cash flow of CN¥56.10 Million could theoretically repay 0% of its total liabilities (CN¥183.42 Million) in one year. See 688089 financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cabio Biotech Wuhan Co Ltd Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Cabio Biotech Wuhan Co Ltd across 12 annual periods. For the full cash flow conversion analysis, see 688089 cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Cabio Biotech Wuhan Co Ltd (2013–2024)
Year-by-year debt coverage analysis for Cabio Biotech Wuhan Co Ltd. Check Cabio Biotech Wuhan Co Ltd cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 1.48x | CN¥173.04 Million | CN¥117.27 Million | ▲ +151.9% |
| 2023 | 0.59x | CN¥68.89 Million | CN¥117.60 Million | ▼ -38.3% |
| 2022 | 0.95x | CN¥176.40 Million | CN¥185.77 Million | ▼ -38.7% |
| 2021 | 1.55x | CN¥103.29 Million | CN¥66.68 Million | ▼ -37.0% |
| 2020 | 2.46x | CN¥145.88 Million | CN¥59.30 Million | ▼ -10.0% |
| 2019 | 2.73x | CN¥131.95 Million | CN¥48.26 Million | ▲ +41.6% |
| 2018 | 1.93x | CN¥106.16 Million | CN¥54.99 Million | ▼ -19.5% |
| 2017 | 2.40x | CN¥100.66 Million | CN¥41.98 Million | ▲ +184.5% |
| 2016 | 0.84x | CN¥62.53 Million | CN¥74.17 Million | ▲ +61.9% |
| 2015 | 0.52x | CN¥44.58 Million | CN¥85.60 Million | ▼ -53.3% |
| 2014 | 1.12x | CN¥46.34 Million | CN¥41.52 Million | ▲ +12.2% |
| 2013 | 0.99x | CN¥39.48 Million | CN¥39.68 Million | — |